Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Correction: Park et al. Genetic Study in Korean Pediatric Patients with Steroid-Resistant Nephrotic Syndrome or Focal Segmental Glomerulosclerosis. J. Clin. Med. 2020, 9, 2013.

Literature DB >> 35683636

Correction: Park et al. Genetic Study in Korean Pediatric Patients with Steroid-Resistant Nephrotic Syndrome or Focal Segmental Glomerulosclerosis. J. Clin. Med. 2020, 9, 2013.

Eujin Park^1,2, Chung Lee^3,4, Nayoung K D Kim^3,4, Yo Han Ahn¹, Young Seo Park⁵, Joo Hoon Lee⁵, Seong Heon Kim⁶, Min Hyun Cho⁷, Heeyeon Cho⁸, Kee Hwan Yoo⁹, Jae Il Shin^10,11, Hee Gyung Kang¹, Il-Soo Ha¹, Woong-Yang Park^3,4,12, Hae Il Cheong¹.

Abstract

In the original article [...].

Entities: Chemical

Year: 2022 PMID： 35683636 PMCID： PMC9181158 DOI： 10.3390/jcm11113016

Source DB: PubMed Journal: J Clin Med ISSN： 2077-0383 Impact factor: 4.964

In the original article [1], there were errors in Tables 2, 3 and S2 as published. The patient SRNS-168 was the only one having COQ2 mutations in the study. However, it was incorrectly described as a mutation in the COQ6 gene. The corrected Table 2, Table 3 and Table S2 appear below. Also, the sentences in Abstract and Results Section 3.2. paragraph 2 have been corrected. “WT1 was the most common causative gene (23.6%), followed by COQ6 (8.7%), NPHS1 (8.7%), NUP107 (7.1%), and COQ8B (6.3%).” “WT1 was the most common causative gene (23.6%, 30 patients), followed by COQ6 (8.7%, 11 patients), NPHS1 (8.7%, 11 patients), NUP107 (7.1%, 9 patients), COQ8B (6.3%, 8 patients), MYH9 (4.7%, 6 patients), and INF2 (4.7%, 6 patients) (Table 2).”

Table 2

Mutation screening results.

Gene	Mode of Inheritance	No. of Patients (%)	% of Total Patients (n = 291)
SRNS/FSGS gene
WT1	AD	30 (23.6%)	10.3%
COQ6	AR	11 (8.7%)	3.8%
NPHS1	AR	11 (8.7%)	3.8%
NUP107	AR	9 (7.1%)	3.1%
COQ8B	AR	8 (6.3%)	2.7%
MYH9	AD	6 (4.7%)	2.1%
INF2	AD	6 (4.7%)	2.1%
PAX2	AD	5 (3.9%)	1.7%
NPHS2	AR	4 (3.1%)	1.4%
MAFB	AD	4 (3.1%)	1.4%
LAMB2	AR	3 (2.4%)	1.0%
SMARCAL1	AR	3 (2.4%)	1.0%
MT-TL1	Mitochondrial	3 (2.4%)	1.0%
ACTN4	AD	1 (0.8%)	0.3%
LMX1B	AD	1 (0.8%)	0.3%
ANLN	AD	1 (0.8%)	0.3%
TRPC6	AD	1 (0.8%)	0.3%
TP53RK	AR	1 (0.8%)	0.3%
PODXL	AR	1 (0.8%)	0.3%
DGKE	AR	1 (0.8%)	0.3%
FOXP3	X-linked	1 (0.8%)	0.3%
LCAT COQ2	AR AR	1 (0.8%) 1 (0.8%)	0.3% 0.3%
Subtotal		113 (89.0%)	38.8%
Phenocopying gene
COL4A5	X-linked	6 (4.7%)	2.1%
COL4A4	AD/AR	4 (3.1%)	1.4%
WDR19	AR	3 (2.4%)	1.0%
COL4A3	AD	1 (0.8%)	0.3%
Subtotal		14 (11.0%)	4.8%
Total		127 (100%)	43.6%

AD, autosomal dominant; AR, autosomal recessive.

Table 3

Genetic studies in large cohorts of pediatric patients with steroid-resistant nephrotic syndrome.

	Trautmann et al., 2015 [3]	Sadowski et al., 2015 [4]	Bierzynska et al., 2017 [2]	Wang et al., 2017 [5]	Warejko et al., 2018 [23]	Nagano et al., 2020 [6]	This Study
Country	International	International	United Kingdom	China	International	Japan	Korea
Modality	GP (31 genes)	GP (27 genes)	WES (53 genes)	GP (28 genes)	WES	GP (60 genes)	Sanger/GP (57 genes) ^c
Detection rate ^a	277/1174 (23.6%)	526/1783 (29.5%)	49/187 (26.2%)	34/120 (28.3%)	85/300 (28.3%)	69/230 (30.0%)	127/291 (43.6%)
Commonly mutated genes ^b	NPHS2 138 (49.8%)	NPHS2 177 (33.7%)	NPHS1 14 (28.6%)	COQ8B 8 (23.5%)	NPHS1 13 (15.3%)	WT1 17 (24.6%)	WT1 30 (23.6%)
	WT1 48 (17.3%)	NPHS1 131 (24.9%)	NPHS2 12 (24.5%)	NPHS1 7 (20.6%)	PLCE1 11 (12.9%)	NPHS1 8 (11.6%)	COQ6 11 (8.7%)
	NPHS1 41 (14.8%)	WT1 85 (16.2%)	WT1 4 (8.2%)	WT1 7 (20.6%)	NPHS2 8 (9.4%)	INF2 8 (11.6%)	NPHS1 11 (8.7%)
	SMARCAL1 12 (4.3%)	PLCE1 37 (7.0%)	NUP107 4 (8.2%)	NPHS2 4 (11.8%)	SMARCAL1 8 (9.4%)	TRPC6 7 (10.1%)	NUP107 9 (7.1%)
	PLCE1 10 (3.6%)	LAMB2 20 (3.8%)	TRPC6 3 (6.1%)	LMX1B 2 (5.9%)	LAMB2 6 (7.1%)	LAMB2 6 (8.7%)	COQ8B 8 (6.3%)

a Overall detection rate of mutations; b The parentheses denote the percentage of total patients with mutations. c WES (n = 4) and polymerase chain reaction-restriction fragment length polymorphism (n = 3) as well; GP, gene panel; WES, whole-exome sequencing.

Table S2

Genotypes and phenotypes of patients with disease-causing mutations.

Gene	Patient ID	Mutations	Age at Onset (Years)	Sex ^b	Family History	Mode of Onset	Kidney Biopsy	Renal Outcome	Time to ESRD (Years)
WT1 (REFSEQ: NM_024426.5)
	SRNS-20	c.1400G > A, p.R467Q	At birth	M	N	NS	ND	ESRD	0.1
	SRNS-42	c.1136delT, p.V379Dfs ^a	6.5	M	N	PU	FSGS	ESRD	2.7
	SRNS-126	c.1231C > T, p.H411Y ^a	1.5	F	N	NS	FSGS	ESRD	7.3
	SRNS-151	c.1315C > T, p.R439C	At birth	M	N	NS	ND	ESRD	0.0
	SRNS-156	c.760C > A, p.P254T ^a	3.3	M	N	NS	FSGS	ESRD	6.1
	SRNS-186	c.1363C > T, p.P455S	8.0	M	Y	NS	FSGS	Normal eGFR	NA
	SRNS-222	c.1316G > A, p.R439H	At birth	M	N	NS	FSGS	ESRD	0.4
	SRNS-223	c.1316G > A, p.R439H	At birth	F	N	NS	DMS	ESRD	0.0
	SRNS-224	c.1316G > A, p.R439H	At birth	F	N	NS	FSGS	Death	NA
	SRNS-225	c.1316G > A, p.R439H	At birth	F	N	NS	ND	ESRD	0.0
	SRNS-226	c.1316G > C, p.R439P	At birth	M	NA	PU	ND	ESRD	1.8
	SRNS-227	c.1315C > T, p.R439C	At birth	F	N	NS	ND	ESRD	0.0
	SRNS-228	c.1324C > A, p.Q442K	1.0	F	N	ESRD	ND	ESRD	0.0
	SRNS-229	c.1372T > A, p.C458S	At birth	M	N	NS	DMS	ESRD	1.1
	SRNS-230	c.1399C > T, p.R467W	At birth	M	N	PU	DMS	ESRD	1.8
	SRNS-231	c.1405G > T, p.D469Y	At birth	F	NA	NS	DMS	ESRD	0.0
	SRNS-232	c.785 − 1G > C in intron 2 ^a	NA	M	NA	NA	ND	NA	NA
	SRNS-233	c.1447 + 4C > T in intron 9	6.6	F	N	NS	FSGS	CKD	NA
	SRNS-234	c.1447 + 4C > T in intron 9	2.6	F	N	NS	FSGS	Normal eGFR	NA
	SRNS-235	c.1447 + 4C > T in intron 9	3.5	M	N	ESRD	ND	ESRD	0.0
	SRNS-236	c.1447 + 4C > T in intron 9	6.8	M	N	NS	MesPGN	ESRD	15.4
	SRNS-237	c.1447 + 4C > T in intron 9	At birth	F	N	CKD	ND	ESRD	0.7
	SRNS-238	c.1447 + 5G > A in intron 9	At birth	M	N	PU	FSGS	ESRD	19.7
	SRNS-239	c.1447 + 5G > A in intron 9	5.0	F	N	NS	FSGS	ESRD	4.2
	SRNS-240	c.1447 + 5G > A in intron 9	6.8	F	N	PU	FSGS	ESRD	12.9
	SRNS-241	c.1447 + 5G > A in intron 9	11.4	M	N	CKD	FSGS	ESRD	0.3
	SRNS-242	c.1447 + 5G > A in intron 9	12.3	M	N	PU	FSGS	Normal eGFR	NA
	SRNS-243	c.1419_1430del12, p.H474_T477del ^a	At birth	M	N	ESRD	ND	ESRD	0.0
	SRNS-244	c.1381T > C, p.C461R	2.2	F	N	ESRD	MesPGN	ESRD	0.0
	SRNS-245	c.1297T > C, p.C433R	At birth	F	N	ESRD	ND	ESRD	0.0
COQ6 (REFSEQ: NM_182476.2)
	SRNS-61	c.686A > C, p.Q229P c.782C > T, p.P261L	1.1	M	N	PU	FSGS	Normal eGFR	NA
	SRNS-103	c.124G > T, p.G42C ^a c. 782C > T, p.P261L	At birth	F	N	NS	FSGS	ESRD	0.4
	SRNS-203	c.484C > T, p.R162* c.782C > T, p.P261L	9.1	M	N	PU	FSGS	ESRD	0.8
	SRNS-251	c.189_191del3, p.K64del c.782C > T, p.P261L	3.9	M	N	NS	FSGS	ESRD	2.2
	SRNS-252	c.189_191del3, p.K64del c.686A > C, p.Q229P	2.0	F	N	NS	FSGS	ESRD	1.1
	SRNS-253	c.189_191del3, p.K64del c.782C > T, p.P261L	3.9	F	N	NS	FSGS	ESRD	0.1
	SRNS-254	c.189_191del3, p.K64del c.782C > T, p.P261L	2.7	F	N	NS	FSGS	ESRD	1.9
	SRNS-255	c.189_191del3, p.K64del c.782C > T, p.P261L	1.2	F	Y	NS	FSGS	ESRD	0.1
	SRNS-256	c.189_191del3, p.K64del c.782C > T, p.P261L	3.1	M	N	NS	FSGS	ESRD	0.4
	SRNS-257	c.686A > C, p.Q229P c.782C > T, p.P261L	At birth	M	N	NS	FSGS	ESRD	1.7
	SRNS-258	c.189_191del3, p.K64del c.782C > T, p.P261L	1.1	M	N	NS	FSGS	ESRD	0.2
NPHS1 (REFSEQ: NM_004646.3)
	SRNS-85	c.2156_2163del8, p.L719Pfs*4 c.2464G > A, p.V822M	At birth	F	Y	NS	MesPGN	Death	0.0
	SRNS-206	c.2156_2163del8, p.L719Pfs4 c.3250dupG, p.V1084Gfs12	At birth	M	N	NS	MesPGN	ESRD	2.5
	SRNS-207	c.2442C > G, p.Y814* c.1379G > A, p.R460Q	At birth	F	N	NS	ND	ESRD	3.0
	SRNS-208	c.188A > G, p.Q63R c.1885G > T, p.E629*	At birth	M	N	NS	FSGS	ESRD	1.6
	SRNS-209	c.3027C > G, p.Y1009* c.3478C > T, p.R1160*	At birth	F	N	NS	ND	ESRD	3.2
	SRNS-210	c.2765C > A, p.A922D c.3287 − 11G > A in intron 24	At birth	M	N	NS	FSGS	CKD	NA
	SRNS-211	c.2156_2163del8, p.L719Pfs4 c.3478C > T, p.R1160	At birth	M	N	NS	ND	ESRD	4.7
	SRNS-212	c.58 + 2T > C in intron 1 ^a c.1338delT, p.I466Mfs*16 ^a	At birth	F	Y	NS	MesPGN	ESRD	1.5
	SRNS-213	c.526 + 1G > A in intron 4 c.1632_1634del3, p.545del	At birth	M	N	NS	ND	Normal eGFR	NA
	SRNS-214	c.3213dupG, p.L1072Afs24 ^a c.3478C > T, p.R1160	At birth	M	N	NS	ND	Death	0.0
	SRNS-215	c.139delG, p.A47Pfs*81 (homozygote)	At birth	M	N	NS	MesPGN	ESRD	1.8
NUP107 (REFSEQ: NM_020401.3)
	SRNS-71	c.934delT, p.Y312Tfs ^a c.2492A > C, p.D831A	4.8	M	N	PU	FSGS	ESRD	8.7
	SRNS-259	c.2071C > T, p.Q691* c.2492A > C, p.D831A	4.3	M	Y	NS	FSGS	ESRD	4.2
	SRNS-260	c.627_663dup37, p.L225Ffs*15 ^a c.2492A > C, p.D831A	3.8	F	N	PU	FSGS	ESRD	3.0
	SRNS-261	c.1079_1083del5, p.E360Gfs*6 c.2492A > C, p.D831A	3.4	M	Y	NS	FSGS	ESRD	2.0
	SRNS-262	c.1079_1083de5l, p.E360Gfs*6 c.2492A > C, p.D831A	2.4	M	N	PU	FSGS	ESRD	2.7
	SRNS-263	c.1079_1083del5, p.E360Gfs*6 c.2492A > C, p.D831A	3.8	M	N	ESRD	ND	ESRD	0.0
	SRNS-264	c.469G > T, p.D157Y c.2492A > C, p.D831A	10.9	F	Y	CKD	FSGS	ESRD	2.1
	SRNS-265	c.1079_1083del5, p.E360Gfs*6 c.2492A > C, p.D831A	4.0	F	N	ESRD	ND	ESRD	0.0
	SRNS-266	c.2492A > C, p.D831A c.1735 − 3T > G in intron 20	4.1	M	Y	PU	FSGS	ESRD	7.4
COQ8B (REFSEQ: NM_024876.3)
	SRNS-25	c.759C > A, p.N253K (homozygote)	1.1	F	NA	NS	FSGS	ESRD	1.5
	SRNS-35	c.737G > A, p.S246N c.532C > T, p.R178W	6.7	M	N	PU	FSGS	CKD	NA
	SRNS-93	c.737G > A, p.S246N c.1548C > A, p.Y516* ^a	9.9	F	N	PU	FSGS	Normal eGFR	NA
	SRNS-246	c.449G > A, p.R150Q c.759C > A, p.N253K	5.1	M	Y	PU	FSGS	ESRD	5.1
	SRNS-247	c.737G > A, p.S246N c.759C > A, p.N253K	10.8	F	N	PU	FSGS	ESRD	2.0
	SRNS-248	c.737G > A, p.S246N (homozygote)	9.2	F	N	PU	FSGS	ESRD	3.0
	SRNS-249	c.737G > A, p.S246N c.1468C > T, p.R490C	6.9	F	N	PU	FSGS	ESRD	3.9
	SRNS-250	c.737G > A, p.S246N (homozygote)	13.0	F	N	PU	FSGS	Normal eGFR	NA
MYH9 (REFSEQ: NM_002473.5)
	SRNS-205	c.3494G > T, p.R1165L	16.8	F	Y	PU	ND	ESRD	17.5
	SRNS-273	c. 2152C > T, p.R718W	1.3	M	N	NS	MesPGN	ESRD	5.3
	SRNS-274	c.287C > T, p.S96L	20.0	M	N	PU	FSGS	ESRD	0.7
	SRNS-275	c.287C > T, p.S96L	12.1	F	N	PU	ND	ESRD	8.3
	SRNS-276	c.2104C > T, p.R702C	8.7	F	NA	PU	MesPGN	ESRD	7.8
	SRNS-277	c.287C > T, p.S96L	12.4	M	NA	PU	MesPGN	ESRD	10.5
INF2 (REFSEQ: NM_022489.3)
	SRNS-63	c.233T > G, p.L78R ^a	11.0	M	N	PU	FSGS	ESRD	6.7
	SRNS-69	c.658G > A, p.E220K	11.1	F	N	PU	FSGS	ESRD	4.0
	SRNS-268	c.658G > A, p.E220K	7.4	M	Y	PU	FSGS	ESRD	5.8
	SRNS-269	c.658G > A, p.E220K	11.7	M	N	NS	FSGS	ESRD	5.5
	SRNS-270	c.230T > C, p.L77P	9.2	F	N	NS	FSGS	ESRD	3.4
	SRNS-271	c.529C > T, p.R177C	12.6	F	Y	PU	FSGS	Normal eGFR	NA
PAX2 (REFSEQ: NM_003987.4)
	SRNS-26	c.76dupG, p.V26Gfs*28	5.3	M	N	PU	FSGS	ESRD	10.2
	SRNS-31	c.563A > G, p.N188S ^a	3.4	M	N	NS	ND	Normal eGFR	NA
	SRNS-32	c.222_225dup4, p.G76Dfs ^a	13.4	M	Y	PU	FSGS	CKD	NA
	SRNS-95	c.74G > A, p.G25E ^a	7.2	F	N	PU	FSGS	ESRD	7.3
	SRNS-191	c.419G > A, p.R140Q	7.8	M	N	PU	FSGS	Normal eGFR	NA
NPHS2 (REFSEQ: NM_014625.3)
	SRNS-27	c.503G > A, p.R168H c.467dupT, p.L156Ffs*11	1.3	F	NA	NS	ND	ESRD	3.6
	SRNS-47	c.412C > T, p.R138* c.503G > A, p.R168H	2.1	M	N	NS	FSGS	ESRD	4.9
	SRNS-136	c.502C > T, p.R168C c.851C > T, p.A284V	6.9	M	N	PU	FSGS	CKD	NA
	SRNS-216	c.358T > C, p.S120P c.503G > A, p.R168H	At birth	M	N	NS	FSGS	ESRD	8.4
COL4A5 (REFSEQ: NM_000495.4)
	SRNS-49	c.834 + 1G > A in intron 14	10.0	F	Y	PU	FSGS	CKD	NA
	SRNS-81	c.956G > A, p.G319D	10.1	M	Y	PU	FSGS	ESRD	10.1
	SRNS-87	c.4946delT, p.L1649Rfs*4 ^a	12.9	M	Y	PU	FSGS	ESRD	6.7
	SRNS-120	c.1165 + 1G > A in intron 19	3.8	M	N	NS	FSGS	ESRD	6.7
	SRNS-134	c.4082T > A, p.L1361* ^a	14.0	M	Y	PU	FSGS	ESRD	8.4
	SRNs-190	c.4532G > A, p.R1511H	12.8	M	N	PU	FSGS	CKD	NA
COL4A4 (REFSEQ: NM_000092.4)
	SRNS-53	c.1111delG, p.D371Tfs ^a c.1323_1340del18, p.P444_L449del	0.8	F	Y	PU	MesPGN	ESRD	18.9
	SRNS-148	c.2630G > A, p.R877Q	3.6	M	N	NS	ND	Death	2.3
	SRNS-152	c.1046G > A, p.R349Q ^a	2.5	F	N	NS	FSGS	Normal eGFR	NA
	SRNS-181	c.2630G > A, p.R877Q	14.3	F	N	PU	FSGS	Normal eGFR	NA
MAFB (REFSEQ: NM_005461.4)
	SRNS-204	c.194G > T, p.S65I	9.8	M	Y	PU	ND	Normal eGFR	NA
	SRNS-280	c.183C > A, p.S61R	12.5	F	N	PU	FSGS	CKD	NA
	SRNS-281	c.211C > G, p.P71A	4.4	M	N	PU	FSGS	ESRD	0.6
	SRNS-282	c.212C > T, p.P71L	1.2	M	N	PU	ND	Normal eGFR	NA
LAMB2 (REFSEQ: NM_002292.3)
	SRNS-217	c.1503_1504delAT, p.C502* c.4267delT, p.C1423Vfs*29	0.7	F	N	NS	FSGS	ESRD	10.8
	SRNS-218	c.2283-2286del4, p.S762Rfs*29 c.536C > T, p.S179F	At birth	F	N	NS	FSGS	CKD	NA
	SRNS-219	c.474delT, p.A159Pfs33 ^a c.1328_1329del2, p.H443Rfs11 ^a	At birth	F	N	NS	ND	ESRD	0.1
WDR19 (REFSEQ: NM_025132.3)
	SRNS-289	c.3533G > A, p.R1178Q c.3703G > A, p.E1235K	9.6	M	N	PU	FSGS	ESRD	1.4
	SRNS-290	c.3533G > A, p.R1178Q c.3703G > A, p.E1235K	6.2	F	Y	PU	MesPGN	ESRD	3.0
	SRNS-291	c.1853T > C, p.L618P c.3533G > A, p.R1178Q	At birth	M	N	CKD	ND	ESRD	0.3
SMARCAL1 (REFSEQ: NM_014140.3)
	SRNS-144	c.1682G > A, p.R561H c.1851 + 1G > T in intron 9 ^a	6.0	M	N	NS	FSGS	ESRD	3.4
	SRNS-287	c.1411dupA, p.I471Nfs ^a c.1484A > C, p.Q495P ^a	5.5	F	N	NS	FSGS	ESRD	1.5
	SRNS-288	c.1484A > C, p.Q495P ^a c.1851 + 1G > T in intron 9 ^a	3.5	M	N	PU	FSGS	ESRD	2.1
MT-TL1 (REFSEQ: NC_012920)
	SRNS-284	mtDNA3243A > G	18.9	F	Y	PU	DMS	CKD	NA
	SRNS-285	mtDNA3243A > G	11.8	F	Y	PU	FSGS	ESRD	6.0
	SRNS-286	mtDNA3243A > G	9.8	F	N	PU	FSGS	ESRD	5.3
FOXP3 (REFSEQ: NM_014009.3)
	SRNS-283	c.736 − 2A > G in intron 7 ^a	3.4	M	N	NS	MNP	Normal eGFR	NA
ACTN4 (REFSEQ: NM_004924.5)
	SRNS-267	c.785C > T, p.S262F	3.5	M	Y	NS	FSGS	ESRD	1.2
LMX1B (REFSEQ: NM_002316.3)
	SRNS-279	c. 668G > A, p.R223Q	2.1	F	N	NS	FSGS	ESRD	1.86
ANLN (REFSEQ: NM_018685.4)
	SRNS-65	c.2305A > T, p.L769* ^a	7.7	M	N	PU	FSGS	Normal eGFR	NA
TRPC6 (REFSEQ: NM_004621.5)
	SRNS-37	c.523C > G, p.R175G ^a	8.5	F	N	PU	FSGS	ESRD	2.3
COL4A3 (REFSEQ: NM_000091.4)
	SRNS-199	c.4793T > G, p.L1598R	0.5	F	N	NS	DMS	ESRD	0.9
TP53RK (REFSEQ: NM_033550.3)
	SRNS-221	c.194A > T, p.K65M (homozygote)	At birth	F	NA	NA	ND	Death	0.0
DGKE (REFSEQ: NM_003647.2)
	SRNS-272	c.501C > G, p.C167W c.610dupA, p.T204Nfs*4	0.5	M	N	PU	FSGS	CKD	NA
LCAT (REFSEQ: NM_000229.1)
	SRNS-278	c.794_801del8, p.E265Afs18 c.931delT, p.F311Lfs99 ^a	9.6	M	Y	PU	FSGS	Normal eGFR	NA
COQ2 (REFSEQ: NM_015697.7)
	SRNS-168	c.392A > G, p.D131G ^a c.518G > A, p.R173H ^a	At birth	F	N	NS	FSGS	ESRD	0.3
PODXL (REFSEQ: NM_005397.3)
	SRNS-220	c.3G > T, p.M1? c.926G > A, p.W309*	At birth	M	Y	NS	ND	ESRD	0.0

a Novel mutations. b Sex of patients with WT1 mutations and sex reversal, followed by their karyotypes. NA, not available; ND, not done; NS, nephrotic syndrome; PU, proteinuria; CKD, chronic kidney disease; ESRD, end-stage renal disease; eGFR, estimated glomerular filtration rate; FSGS, focal segmental glomerulosclerosis; DMS, diffuse mesangial sclerosis; MesPGN, mesangial proliferative glomerulonephritis; MNP, membranous nephropathy; M, male; F, female; Y, yes; N, no.

The authors apologize for any inconvenience caused and state that the scientific conclusions are unaffected. The original article has been updated.

1 in total

1. Genetic Study in Korean Pediatric Patients with Steroid-Resistant Nephrotic Syndrome or Focal Segmental Glomerulosclerosis.

Authors: Eujin Park; Chung Lee; Nayoung K D Kim; Yo Han Ahn; Young Seo Park; Joo Hoon Lee; Seong Heon Kim; Min Hyun Cho; Heeyeon Cho; Kee Hwan Yoo; Jae Il Shin; Hee Gyung Kang; Il-Soo Ha; Woong-Yang Park; Hae Il Cheong
Journal: J Clin Med Date: 2020-06-26 Impact factor: 4.241

1 in total